# Lumasiran in Hyperoxalaemic Patients on Haemodialysis

> **NCT06225544** · PHASE2 · RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 50 (estimated)

## Conditions studied

- Haemodialysis
- Chronic Kidney Disease Requiring Chronic Dialysis
- Cardiovascular Disease
- Cardiovascular Risk Factor
- Hyperoxalemia

## Interventions

- **DRUG:** Lumasiran
- **DRUG:** 0.9% Sodium Chloride (placebo)

## Key facts

- **NCT ID:** NCT06225544
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-14
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225544, "Lumasiran in Hyperoxalaemic Patients on Haemodialysis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06225544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*